Is zolbetuximab a self-paid drug or a medically insured drug?

Zoltuximab (zolbetuximab) is a new type of targeted drug that is mainly used to treat specific types of cancer, especially showing good potential in the treatment of digestive system tumors such as gastric cancer. The drug works by targeting the Clark factor receptor (CLCNF), thereby preventing the growth and spread of cancer cells. As an innovative anti-cancer drug, the original drug zotuximab has been launched in the domestic market, providing a treatment option for patients with certain cancer types. However, despite its certain advantages in therapeutic efficacy, zotuximab is not currently included in China's medical insurance catalog.

This means that zotuximab remains a self-pay medicine, and patients generally have to bear the cost of treatment themselves if they choose to use it. According to market feedback, the price of zotuximab is relatively high, and patients may need to pay a greater financial burden when using it, especially during long-term treatment with the drug. Specific prices can be found out through hospitals or pharmacies, because the selling price of drugs will be affected by different regions, hospitals, and policy factors.

Due to the high price of zotuximab, not being included in medical insurance may cause some patients to face greater financial pressure when using it. Drugs not covered by medical insurance often require patients to pay in full, which is undoubtedly a big challenge for many patients with difficult financial conditions. With the continuous research and clinical application of this drug in terms of therapeutic effects, it may be gradually included in the medical insurance system through policy changes in the future, thereby reducing the financial burden on patients.

In general, zotuximab, as a targeted therapy drug, is still a self-funded drug and has not yet entered the medical insurance system. Patients should communicate with their doctors when choosing treatment to understand the specific prices and payment methods of the drugs, and pay attention to changes in relevant medical insurance policies to reduce treatment costs under possible medical insurance coverage in the future.

References: https://www.astellas.com/en/news/29401